{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T06:11:10Z","timestamp":1794204670698,"version":"4.8.0"},"reference-count":83,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Clinical Research F"},{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","award":["3M190551"],"award-info":[{"award-number":["3M190551"]}],"id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","award":["C14\/21\/103"],"award-info":[{"award-number":["C14\/21\/103"]}],"id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Inflammatory bowel disease [IBD] is associated with various immune-mediated disorders including spondylarthritis, pyoderma gangrenosum, primary sclerosing cholangitis, and uveitis. Chronic kidney disease [CKD] is defined by a reduction in kidney function (estimated glomerular filtration rate [eGFR] less than 60 ml\/min\/1.73m2] and\/or damage markers that are present for at least 3 months, regardless of the aetiology. Case reports and cohort studies suggest that IBD is associated with CKD. The extent and magnitude of a potential association is unknown. A comprehensive search was conducted in EMBASE, MEDLINE, Web of Science, the Cochrane database, and SCOPUS. Two separate reviewers were involved in the process of article selection and evaluation. Odds ratios were calculated in those papers with a comparison between an IBD population and a non-IBD control population, the Mantel Haenszel test was employed, using a random effect model. The systematic review was registered in PROSPERO [RD42023381927]. A total of 54 articles was included in the systematic review. Of these, eight articles included data on prevalence of CKD in IBD patients [n\u2005=\u2005102\u2005230] vs healthy populations [n\u2005=\u2005762\u2005430]. Of these, diagnosis of CKD was based on International Classification of Diseases [ICD] codes in five studies vs on eGFR in three studies. The overall odds ratio of developing CKD in the IBD population is 1.59, [95% CI 1.31-1.93], without any difference between studies using diagnostic coding (odds ratio [OR] 1.70, 95% CI 1.33-2.19] vs diagnosis based on eGFR [OR 1.36, 95% CI 1.33-1.64]. IBD is associated with a clinically meaningful increased CKD prevalence. We provide recommendations on diagnostic evaluation, as well as suggestions for future research.<\/jats:p>","DOI":"10.1093\/ecco-jcc\/jjae049","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T19:50:40Z","timestamp":1712346640000},"page":"1464-1475","source":"Crossref","is-referenced-by-count":20,"title":["Chronic Kidney Disease in Inflammatory Bowel Disease: a Systematic Review and Meta-analysis"],"prefix":"10.1093","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9958-3474","authenticated-orcid":false,"given":"Ward","family":"Zadora","sequence":"first","affiliation":[{"name":"Nephrology and Renal Transplantation Research Group , KULeuven, Leuven , Belgium"},{"name":"Translational Research in GastroIntestinal Disorders , KULeuven, Leuven , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2154-0490","authenticated-orcid":false,"given":"Tommaso","family":"Innocenti","sequence":"additional","affiliation":[{"name":"Translational Research in GastroIntestinal Disorders , KULeuven, Leuven , Belgium"},{"name":"Department of Experimental and Clinical Biomedical Sciences, University of Florence , Florence , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3898-7093","authenticated-orcid":false,"given":"Bram","family":"Verstockt","sequence":"additional","affiliation":[{"name":"Translational Research in GastroIntestinal Disorders , KULeuven, Leuven , Belgium"},{"name":"Department of Gastroenterology and Hepatology, University Hospitals Leuven , KULeuven, Leuven , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2846-2026","authenticated-orcid":false,"given":"Bjorn","family":"Meijers","sequence":"additional","affiliation":[{"name":"Nephrology and Renal Transplantation Research Group , KULeuven, Leuven , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,8]]},"reference":[{"key":"2024090305533299600_CIT0001","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn\u2019s disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"key":"2024090305533299600_CIT0002","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"2024090305533299600_CIT0003","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jama.2023.15389","article-title":"Ulcerative colitis in adults: a review","volume":"330","author":"Gros","year":"2023","journal-title":"JAMA"},{"key":"2024090305533299600_CIT0004","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.mayocp.2014.07.002","article-title":"Ulcerative colitis: epidemiology, diagnosis, and management","volume":"89","author":"Feuerstein","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"2024090305533299600_CIT0005","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"2024090305533299600_CIT0006","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41575-020-00360-x","article-title":"The four epidemiological stages in the global evolution of inflammatory bowel disease","volume":"18","author":"Kaplan","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2024090305533299600_CIT0007","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1111\/j.1523-1755.2005.00365.x","article-title":"Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes [KDIGO]","volume":"67","author":"Levey","year":"2005","journal-title":"Kidney Int"},{"key":"2024090305533299600_CIT0008","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","article-title":"Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline","volume":"158","author":"Stevens","year":"2013","journal-title":"Ann Intern Med"},{"key":"2024090305533299600_CIT0009","first-page":"S117","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume-title":"Kidney Int","author":"Paul Stevens","year":"2024"},{"key":"2024090305533299600_CIT0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: an update 2022","volume":"12","author":"Kovesdy","year":"2022","journal-title":"Kidney Int Suppl"},{"key":"2024090305533299600_CIT0011","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1572-0241.1998.156_b.x","article-title":"Renal and urologic complications of inflammatory bowel disease","volume":"93","author":"Pardi","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"2024090305533299600_CIT0012","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/ecco-jcc\/jjv138","article-title":"Renal involvement in inflammatory bowel diseases","volume":"10","author":"Corica","year":"2016","journal-title":"J Crohns Colitis"},{"key":"2024090305533299600_CIT0013","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00535-022-01903-6","article-title":"Renal manifestations in inflammatory bowel disease: a systematic review","volume":"57","author":"van Hoeve","year":"2022","journal-title":"J Gastroenterol"},{"key":"2024090305533299600_CIT0014","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.dld.2021.11.008","article-title":"Kidney function monitoring in inflammatory bowel disease: the monitored consensus","volume":"54","author":"Guillo","year":"2022","journal-title":"Dig Liver Dis"},{"key":"2024090305533299600_CIT0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols [PRISMA-P] 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"2024090305533299600_CIT0016","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"2024090305533299600_CIT0017","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with r: A practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"key":"2024090305533299600_CIT0018","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/apt.16444","article-title":"Comorbidity before and after a diagnosis of inflammatory bowel disease","volume":"54","author":"Bernstein","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2024090305533299600_CIT0019","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2005.06.021","article-title":"The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study","volume":"129","author":"Bernstein","year":"2005","journal-title":"Gastroenterology"},{"key":"2024090305533299600_CIT0020","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1016\/j.cgh.2019.10.043","article-title":"Inflammatory bowel diseases are associated with an increased risk for chronic kidney disease, which decreases with age","volume":"18","author":"Vajravelu","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024090305533299600_CIT0021","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.3748\/wjg.v24.i42.4798","article-title":"Increased end-stage renal disease risk in patients with inflammatory bowel disease: a nationwide population-based study","volume":"24","author":"Park","year":"2018","journal-title":"World J Gastroenterol"},{"key":"2024090305533299600_CIT0022","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3748\/wjg.v26.i4.404","article-title":"Trends and risk factors of elderly-onset Crohn\u2019s disease: a nationwide cohort study","volume":"26","author":"Moon","year":"2020","journal-title":"World J Gastroenterol"},{"key":"2024090305533299600_CIT0023","first-page":"363","article-title":"Investigation of chronic diseases in patients with inflammatory bowel disease: a hospital-based case-control study","volume":"13","author":"Zabihi","year":"2022","journal-title":"Caspian J Intern Med"},{"key":"2024090305533299600_CIT0024","doi-asserted-by":"crossref","first-page":"138","DOI":"10.14309\/ajg.0000000000002473","article-title":"Absolute and relative risks of kidney and urological complications in patients with inflammatory bowel disease","volume":"119","author":"Yang","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2024090305533299600_CIT0025","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.amepre.2023.08.008","article-title":"Inflammatory bowel disease with chronic kidney disease and acute kidney injury","volume":"65","author":"Liu","year":"2023","journal-title":"Am J Prev Med"},{"key":"2024090305533299600_CIT0026","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1053\/j.gastro.2004.03.016","article-title":"5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study","volume":"126","author":"Van Staa","year":"2004","journal-title":"Gastroenterology"},{"key":"2024090305533299600_CIT0027","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/ndt\/gfaa378","article-title":"Immunoglobulin a nephropathy in association with inflammatory bowel diseases: Results from a national study and systematic literature review","volume":"37","author":"Joher","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2024090305533299600_CIT0028","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1681\/ASN.2020060848","article-title":"Inflammatory bowel disease is more common in patients with IGA nephropathy and predicts progression of ESKD: a Swedish population-based cohort study","volume":"32","author":"Rehnberg","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2024090305533299600_CIT0029","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/ibd\/izaa308","article-title":"Disease-and treatment-related complications in older patients with inflammatory bowel diseases: comparison of adult-onset vs elderly-onset disease","volume":"27","author":"Rozich","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2024090305533299600_CIT0030","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.21608\/ejhm.2022.256613","article-title":"Renal status of inflammatory bowel disease patients in Assiut university hospital: single center study","volume":"89","author":"Khalifa","year":"2022","journal-title":"Egypt J Hosp Med"},{"key":"2024090305533299600_CIT0031","first-page":"1846","article-title":"Frequency and risk factors of renal insufficiency in inflammatory bowel disease inpatients","volume":"19","author":"Lewis","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"2024090305533299600_CIT0032","first-page":"381","article-title":"Patterns of renal involvement in a cohort of patients with inflammatory bowel disease in Egypt","volume":"81","author":"Elaziz","year":"2018","journal-title":"Acta Gastroenterol Belg"},{"key":"2024090305533299600_CIT0033","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s12882-022-02883-8","article-title":"The pathological and outcome characteristics of renal lesions in Crohn\u2019s disease","volume":"23","author":"Yang","year":"2022","journal-title":"BMC Nephrol"},{"key":"2024090305533299600_CIT0034","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jcma.2016.08.009","article-title":"Gastrointestinal complications and extraintestinal manifestations of inflammatory bowel disease in Taiwan: a population-based study","volume":"80","author":"Hsu","year":"2017","journal-title":"J Chin Med Assoc"},{"key":"2024090305533299600_CIT0035","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.3748\/wjg.v9.i10.2300","article-title":"Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study","volume":"9","author":"Lakatos","year":"2003","journal-title":"World J Gastroenterol"},{"key":"2024090305533299600_CIT0036","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00005792-199209000-00001","article-title":"Amyloidosis and inflammatory bowel disease. a 50-year experience with 25 patients","volume":"71","author":"Greenstein","year":"1992","journal-title":"Medicine [Baltim]"},{"key":"2024090305533299600_CIT0037","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.crohns.2009.11.009","article-title":"Systemic amyloidosis in inflammatory bowel disease: retrospective study on its prevalence, clinical presentation, and outcome","volume":"4","author":"Serra","year":"2010","journal-title":"J Crohns Colitis"},{"key":"2024090305533299600_CIT0038","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4321\/S1130-01082011000500009","article-title":"Amyloidosis and Crohn\u2019s disease","volume":"103","author":"Guardiola-Ar\u00e9valo","year":"2011","journal-title":"Rev Esp Enferm Dig"},{"key":"2024090305533299600_CIT0039","first-page":"504","article-title":"Secondary systemic amyloidosis in inflammatory bowel disease: a nationwide analysis","volume":"30","author":"Sharma","year":"2017","journal-title":"Ann Gastroenterol"},{"key":"2024090305533299600_CIT0040","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/apt.15408","article-title":"No increased risk of nephrotoxicity associated with 5-aminosalicylic acid in IBD: a population-based cohort and nested case-control study","volume":"50","author":"Jairath","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2024090305533299600_CIT0041","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1007\/s00228-012-1289-3","article-title":"Comparison of the effect of mesalazine and sulfasalazine on laboratory parameters: a retrospective observational study","volume":"68","author":"Masuda","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"2024090305533299600_CIT0042","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/gut.40.6.761","article-title":"Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate","volume":"40","author":"Schreiber","year":"1997","journal-title":"Gut"},{"key":"2024090305533299600_CIT0043","doi-asserted-by":"crossref","first-page":"83","DOI":"10.5414\/CNP61083","article-title":"Renal impairment in patients with inflammatory bowel disease: association with aminosalicylate therapy","volume":"61","author":"Elseviers","year":"2004","journal-title":"Clin Nephrol"},{"key":"2024090305533299600_CIT0044","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1097\/01.MIB.0000185402.65288.19","article-title":"5-aminosalicylates and effects on renal function in patients with Crohn\u2019s disease","volume":"11","author":"de Jong","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"2024090305533299600_CIT0045","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00054725-199911000-00001","article-title":"Combination therapy with oral tacrolimus [fk506] and azathioprine or 6-mercaptopurine for treatment-refractory Crohn\u2019s disease perianal fistulae","volume":"5","author":"Lowry","year":"1999","journal-title":"Inflamm Bowel Dis"},{"key":"2024090305533299600_CIT0046","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/j.1572-0241.2007.01718.x","article-title":"Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease","volume":"103","author":"Sternthal","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"2024090305533299600_CIT0047","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.3390\/jcm9061771","article-title":"Effectiveness and nephrotoxicity of long-term tacrolimus administration in patients with ulcerative colitis","volume":"9","author":"Haga","year":"2020","journal-title":"J Clin Med"},{"key":"2024090305533299600_CIT0048","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000524594","article-title":"Risk factors for nephrotoxicity due to tacrolimus therapy for ulcerative colitis","volume":"103","author":"Nakata","year":"2022","journal-title":"Digestion"},{"key":"2024090305533299600_CIT0049","doi-asserted-by":"crossref","first-page":"e278","DOI":"10.3346\/jkms.2021.36.e278","article-title":"Severe disease activity based on the Paris classification is associated with the development of extraintestinal manifestations in Korean children and adolescents with ulcerative colitis","volume":"36","author":"Jang","year":"2021","journal-title":"J Korean Med Sci"},{"key":"2024090305533299600_CIT0050","doi-asserted-by":"crossref","first-page":"162","DOI":"10.5114\/polp.2019.85370","article-title":"Extraintestinal manifestations in paediatric-onset inflammatory bowel disease depending on disease location and activity","volume":"94","author":"Niewiem","year":"2019","journal-title":"Pediatria Polska"},{"key":"2024090305533299600_CIT0051","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/ped.12547","article-title":"Descriptive epidemiology of children hospitalized for inflammatory bowel disease in Japan: inpatient database analysis","volume":"57","author":"Takeuchi","year":"2015","journal-title":"Pediatr Int"},{"key":"2024090305533299600_CIT0052","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3345\/kjp.2018.06485","article-title":"Renal involvement in children and adolescents with inflammatory bowel disease","volume":"61","author":"Jang","year":"2018","journal-title":"Korean J Pediatr"},{"key":"2024090305533299600_CIT0053","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1093\/ibd\/izy166","article-title":"Pediatric inflammatory bowel diseases: should we be looking for kidney abnormalities","volume":"24","author":"Lauritzen","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2024090305533299600_CIT0054","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/MPG.0000000000003682","article-title":"Prevalence and etiologies of renal and urinary manifestations in a large cohort of children with inflammatory bowel disease","volume":"76","author":"Cordesse","year":"2023","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2024090305533299600_CIT0055","doi-asserted-by":"crossref","first-page":"e936497","DOI":"10.12659\/MSM.936497","article-title":"Renal manifestations in inflammatory bowel disease: a cohort study during the biologic era","volume":"28","author":"Dincer","year":"2022","journal-title":"Med Sci Monit"},{"key":"2024090305533299600_CIT0056","doi-asserted-by":"crossref","first-page":"e630","DOI":"10.1016\/j.crohns.2013.05.001","article-title":"Renal insufficiency in IBD: prevalence and possible pathogenetic aspects","volume":"7","author":"Primas","year":"2013","journal-title":"J Crohns Colitis"},{"key":"2024090305533299600_CIT0057","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s40620-018-0529-8","article-title":"Comparing the impact of older age on outcome in chronic kidney disease of different etiologies: a prospective cohort study","volume":"31","author":"Raman","year":"2018","journal-title":"J Nephrol"},{"key":"2024090305533299600_CIT0058","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.rdc.2018.06.007","article-title":"Renal manifestations of inflammatory bowel disease","volume":"44","author":"Ambruzs","year":"2018","journal-title":"Rheum Dis Clin North Am"},{"key":"2024090305533299600_CIT0059","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00428-022-03373-w","article-title":"Crohn\u2019s disease may promote inflammation in IgA nephropathy: a case\u2013control study of patients undergoing kidney biopsy","volume":"481","author":"Akiyama","year":"2022","journal-title":"Virchows Arch"},{"key":"2024090305533299600_CIT0060","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1093\/ecco-jcc\/jjw080","article-title":"Amyloidosis in inflammatory bowel disease: A systematic review of epidemiology, clinical features, and treatment","volume":"10","author":"Tosca Cuquerella","year":"2016","journal-title":"J Crohns Colitis"},{"key":"2024090305533299600_CIT0061","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1056\/NEJMoa070265","article-title":"Natural history and outcome in systemic AA amyloidosis","volume":"356","author":"Lachmann","year":"2007","journal-title":"N Engl J Med"},{"key":"2024090305533299600_CIT0062","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13075-015-0612-7","article-title":"Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: Results from a randomised controlled trial","volume":"17","author":"Kremer","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2024090305533299600_CIT0063","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: Medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2024090305533299600_CIT0064","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/gutjnl-2017-315568","article-title":"Natural disease course of Crohn\u2019s disease during the first 5 years after diagnosis in a European population-based inception cohort: an EPI-IBDstudy","volume":"68","author":"Burisch","year":"2019","journal-title":"Gut"},{"key":"2024090305533299600_CIT0065","first-page":"500","article-title":"The use of 5-aminosalicylates in Crohn\u2019s disease: a retrospective study using the UK clinical practice research datalink","volume":"33","author":"Hart","year":"2020","journal-title":"Ann Gastroenterol"},{"key":"2024090305533299600_CIT0066","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/apt.17419","article-title":"5-aminosalicylate maintenance is not superior to no maintenance in patients with newly diagnosed Crohn\u2019s disease: a nationwide cohort study","volume":"57","author":"Atia","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"2024090305533299600_CIT0067","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/14712598.2019.1666101","article-title":"Modern use of 5-aminosalicylic acid compounds for ulcerative colitis","volume":"20","author":"Le Berre","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"2024090305533299600_CIT0068","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/ecco-jcc\/jjab177","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: surgical treatment","volume":"16","author":"Spinelli","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2024090305533299600_CIT0069","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2468-1253(16)30003-6","article-title":"Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis [construct]: a mixed methods, open-label, pragmatic randomised trial","volume":"1","author":"Williams","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024090305533299600_CIT0070","first-page":"370","article-title":"Infliximab is more effective than cyclosporine as a rescue therapy for acute severe ulcerative colitis: a retrospective single-center study","volume":"34","author":"Grazie","year":"2021","journal-title":"Ann Gastroenterol"},{"key":"2024090305533299600_CIT0071","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41572-020-0213-x","article-title":"Pyoderma gangrenosum","volume":"6","author":"Maverakis","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2024090305533299600_CIT0072","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024090305533299600_CIT0073","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease: Medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2024090305533299600_CIT0074","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/ueg2.12305","article-title":"Landscape of new drugs and targets in inflammatory bowel disease","volume":"10","author":"Vieujean","year":"2022","journal-title":"United European Gastroenterol J"},{"key":"2024090305533299600_CIT0075","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s13643-018-0915-2","article-title":"The risk of bias in observational studies of exposures [robins-e] tool: Concerns arising from application to observational studies of exposures","volume":"7","author":"Bero","year":"2018","journal-title":"Syst Rev"},{"key":"2024090305533299600_CIT0076","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"rd European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016: Part 1: diagnosis and medical management","volume":"11","author":"Gomoll\u00f3n","year":"2016","journal-title":"J Crohns Colitis"},{"key":"2024090305533299600_CIT0077","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"2024090305533299600_CIT0078","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/ajg.2009.727","article-title":"Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, practice parameters committee","volume":"105","author":"Kornbluth","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"2024090305533299600_CIT0079","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1053\/j.gastro.2020.08.060","article-title":"AGA clinical practice update on management of inflammatory bowel disease in elderly patients: expert review","volume":"160","author":"Ananthakrishnan","year":"2021","journal-title":"Gastroenterology"},{"key":"2024090305533299600_CIT0080","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.crohns.2012.08.013","article-title":"5-aminosalicylates and renal function monitoring in inflammatory bowel disease: a nationwide survey","volume":"7","author":"Zallot","year":"2013","journal-title":"J Crohns Colitis"},{"key":"2024090305533299600_CIT0081","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1097\/MEG.0000000000002008","article-title":"Knowledge of 5-aminosalicylic acid nephrotoxicity and adherence to kidney function monitoring of patients with inflammatory bowel disease","volume":"33","author":"Weislinger","year":"2021","journal-title":"European J Gastroenterol Hepatol"},{"key":"2024090305533299600_CIT0082","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1136\/flgastro-2014-100452","article-title":"Do gastroenterologists monitor their patients taking 5-amino-salicylates following initiation of treatment","volume":"6","author":"Siddique","year":"2015","journal-title":"Frontline Gastroenterol"},{"key":"2024090305533299600_CIT0083","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.3390\/jcm11112954","article-title":"Lack of monitoring is associated with risk of acute kidney events among patients with inflammatory bowel disease","volume":"11","author":"Achit","year":"2022","journal-title":"J Clin Med"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjae049\/57340808\/jjae049.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/18\/9\/1464\/58903590\/jjae049.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/18\/9\/1464\/58903590\/jjae049.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T15:28:48Z","timestamp":1731684528000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/18\/9\/1464\/7641963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,8]]},"references-count":83,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,4,8]]},"published-print":{"date-parts":[[2024,9,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae049","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,4,8]]}}}